Researchers have developed new tools to better understand the role of Bifidobacterium breve, revealing its competitive growth strategies and potential for supporting the immune system.
Is the microbiome just a trend or the future of health? Welcome to the first article of the Bold Column.
Delayed microbiota maturation in infants with cystic fibrosis could contribute to disease complications, highlighting potential therapeutic targets.
Understanding the complex interactions between exercise, diet and gut health can help to develop approaches to influence the gut microbiota, boost immunity and prevent or manage gastrointestinal diseases.
Professor Jacques Ravel, from University of Maryland School of Medicine and LUCA Biologics, discusses his latest research and therapeutic innovations in the field of vaginal microbiome modulation.
Phages could be used as a drug delivery system for conditions such as inflammation and obesity.
Microbiota analysis could help sexual assault investigations by detecting microbial markers of contact, even in cases where traditional DNA evidence is lacking.
Celine Druart, from the Pharmabiotic Research Institute, discusses the new European regulation concerning substances of human origin and the impact on microbiome research and therapeutic development.
Preclinical findings will be presented at the American Association for Cancer Research (AACR) Annual Meeting in Chicago.
L-ornithine can be an additional therapy to boost the efficacy of ustekinumab in people with Crohn’s disease.
